坎伯兰制药公司将公布2025年第一季度财务结果及公司更新-动脉网

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

CISION 等信源发布 2025-04-30 04:05



可切换为仅中文







NASHVILLE, Tenn.

田纳西州纳什维尔

，

April 29, 2025

2025年4月29日

/PRNewswire/ --

Cumberland Pharmaceuticals Inc.

坎伯兰制药公司

(Nasdaq:

（纳斯达克：

CPIX

), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on

)，一家专业制药公司，今天宣布将在市场收盘后发布其2025年第一季度财务业绩，并提供公司最新动态。

Tuesday, May 6, 2025

2025年5月6日，星期二

。

A conference call will be held on

将举行一次电话会议

May 6

5月6日

在

4:30 p.m. Eastern Time

下午4点30分（东部时间）

to discuss the results and update.

讨论结果并进行更新。

The link to register is:

注册链接为：

https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f

。

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a 'Call Me' option to have the system automatically call them at the start of the conference.

一旦注册，参与者可以使用将提供给他们的拨入号码和个人识别码（PIN）从电话拨入。或者，他们可以选择“回呼”选项，让系统在会议开始时自动呼叫他们。

A replay of the call will be available for one year and can be accessed via

电话会议的重播将提供一年，并且可以通过以下方式访问

Cumberland's

坎伯兰的

website or by visiting

网站或通过访问

https://edge.media-server.com/mmc/p/wost2na9/

。

Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

Cumberland Pharmaceuticals是一家专注于提供独特产品的专业制药公司，致力于改善患者护理。该公司为医院急症护理、胃肠病学和肿瘤学市场开发、收购并推广产品。

The company's portfolio of FDA-approved brands includes:

公司经FDA批准的品牌组合包括：

Acetadote

乙酰半胱氨酸

(

acetylcysteine

乙酰半胱氨酸

) injection, for the treatment of acetaminophen poisoning;

）注射剂，用于治疗对乙酰氨基酚中毒；

Caldolor

(

ibuprofen

布洛芬

) injection, for the treatment of pain and fever;

）注射，用于治疗疼痛和发烧；

Kristalose

晶体糖

(

lactulose

乳果糖

) for oral solution, a prescription laxative, for the treatment of constipation;

用于口服溶液，一种处方泻药，用于治疗便秘；

Sancuso

格拉司琼透皮贴片

(

granisetron)

格拉司琼)

transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;

经皮系统，用于预防接受某些类型化疗的患者的恶心和呕吐；

Vaprisol

(

conivaptan

康尼伐坦

) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and

）注射，用于提高住院的等容量和高容量低钠血症患者的血清钠水平；以及

Vibativ

维巴特

(

telavancin

特拉万星

) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

）注射剂，用于治疗某些严重的细菌感染，包括医院获得性细菌性肺炎和呼吸机相关性细菌肺炎，以及复杂的皮肤和皮肤结构感染。

The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.

公司还有一系列二期临床项目正在进行中，评估其候选产品 ifetroban 在系统性硬化症、与杜氏肌营养不良相关的心肌病及特发性肺纤维化患者中的应用。

For more information on

有关更多信息，请参阅

Cumberland's

坎伯兰的

approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at

批准的产品，包括完整的处方信息，请访问公司网站上找到的各个产品网站的链接。

www.cumberlandpharma.com

。

SOURCE Cumberland Pharmaceuticals Inc.

来源：坎伯兰制药公司

WANT YOUR COMPANY'S NEWS